Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

类风湿性关节炎 医学 甲氨蝶呤 内科学 随机对照试验 荟萃分析 药理学
作者
Dan Ouyang,Yuan Zhi,Jie Zou,Yong Long Wang,Zheng Chen,Yu Ying Yang,Bin Zou,Xin Li,Jian Zhong Cao
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:13 被引量:8
标识
DOI:10.3389/fphar.2022.911810
摘要

Objectives: We aimed to estimate the effectiveness and safety of iguratimod (IGU) monotherapy or in combination with methotrexate (MTX) in treating rheumatoid arthritis (RA) to provide an evidence-primarily-based foundation for clinical application. Methods: We conducted a systematic review of the meta-analysis using eight databases and two clinical trial websites searching for randomized controlled trials (RCTs) from conception to 15 March 2022, based on outcomes of patients with RA treated with IGU. The evidence quality assessment of primary outcomes was evaluated by the GRADE tool, and RevMan 5.3 and StataMP 14.0 were used to perform this research. Results: A total of 4302 patients with RA from 38 RCTs was included in this research. Pooled results demonstrated as follows: 1) Compared with methotrexate (MTX) alone, IGU alone was superior in improving ACR20 and DAS28-ESR, while having no significant difference in ACR50 and ACR70 [ACR20: (RR 1.15, 95% CI 1.05-1.27, p = 0.004); ACR50: (RR 0.97, 95% CI 0.66-1.44, p = 0.88); ACR70: (RR 0.92, 95% CI 0.45-1.90, p = 0.83); DAS28-ESR: mean difference (MD) -0.15, 95% CI -0.27 to -0.03, p = 0.01]. 2) Compared with MTX alone, IGU + MTX was more effective in improving ACR20, ACR50, ACR70, and DAS28-ESR. [ACR20: (RR 1.24, 95% CI 1.14-1.35, p < 0.00001); ACR50: (RR 1.96, 95% CI 1.62-2.39, p <0.00001); ACR70: (RR 1.91, 95% CI 1.41-2.57, p < 0.0001)]; [DAS28-ESR: (MD) -1.43, 95% CI -1.73 to -1.12, p < 0.00001]. 3) Compared with MTX + leflunomide (LEF), ACR20, ACR50, ACR70, and DAS28-ESR of IGU + MTX had no significant difference [ACR20: (RR 1.06, 95% CI 0.94-1.19, p = 0.38); ACR50: (RR 1.10, 95% CI 0.66-1.84, p = 0.72); ACR70: (RR 1.20, 95% CI 0.45-3.20, p = 0.71); DAS28-ESR: (MD -0.02, 95% CI -0.13 to -0.10, p = 0.77)]. 4) Compared with MTX + hydroxychloroquine (HCQ), IGU + MTX was superior in improving DAS28-ESR (MD -2.16, 95% CI -2.53 to -1.79, p < 0.00001). 5) Compared with MTX + tripterygium glycosides (TGs), IGU + MTX was more effective in improving DAS28-ESR (MD -0.94, 95% CI -2.36 to 0.48, p = 0.19). 6) There were no significant differences in adverse events (AEs) between the groups of IGU vs. MTX (RR 0.96, 95% CI 0.71-1.31, p = 0.80), IGU + MTX vs. MTX (RR 1.10, 95% CI 0.90-1.35, p = 0.34), IGU + MTX vs. MTX + HCQ (RR 0.64, 95% CI 0.29-1.42, p = 0.27), and IGU + MTX vs. MTX + TGs (RR 0.75, 95% CI 0.28-2.02, p = 0.57). The incidence of AEs in the IGU + MTX group was lower than the MTX + LEF group (RR 0.83, 95% CI 0.71-0.98, p = 0.03). Conclusion: Compared to the MTX alone subgroup, IGU alone offers clear advantages in improving ACR20 and DAS28-ESR, despite the insufficient evidence for DAS28-ESR findings. IGU + MTX shows clear benefits in improving ACR20, ACR50, ACR70, and DAS28-ESR scores compared to standard therapies. When the intervention (IGU alone or IGU + MTX) lasted for 52 weeks, it demonstrated superior efficacy in improving ACR20 of patients without prominent adverse events. Notably, IGU or IGU + MTX has apparent advantages in improving ACR20 of first-visit RA, and IGU + MTX has obvious advantages in improving DAS28-ESR of refractory RA. Furthermore, IGU + MTX does not increase the risk of leukopenia, but it can decrease the risk of liver function tests (LFTs), regardless of the age or the stage of RA. Clinical Trial Registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD42022295217.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shouz完成签到,获得积分10
刚刚
Waiting完成签到 ,获得积分10
1秒前
kkdsseed的应助被hqc8866采纳,获得10
1秒前
toppkj发布了新的文献求助10
1秒前
123wzl123完成签到,获得积分10
1秒前
xiaoxiao完成签到 ,获得积分10
2秒前
芷诺完成签到 ,获得积分10
2秒前
yanglala完成签到 ,获得积分10
3秒前
英勇含烟完成签到,获得积分10
3秒前
快乐谷蓝完成签到,获得积分10
3秒前
qss完成签到,获得积分10
4秒前
云朵杰瑞完成签到,获得积分10
4秒前
许自通完成签到,获得积分10
4秒前
云中月完成签到,获得积分10
5秒前
妩媚的问玉完成签到,获得积分10
5秒前
无敌干扰素完成签到,获得积分10
7秒前
TonyXWZhang完成签到,获得积分10
8秒前
在九月完成签到 ,获得积分10
8秒前
fishswim1完成签到,获得积分10
10秒前
刘华珍完成签到,获得积分10
12秒前
12秒前
段辉完成签到,获得积分10
13秒前
Lucas的应助被toppkj采纳,获得10
14秒前
lizhehao完成签到,获得积分10
14秒前
香蕉觅云的应助被紫熊采纳,获得10
14秒前
TY完成签到 ,获得积分10
15秒前
szjqq完成签到,获得积分10
15秒前
rzxhygr完成签到,获得积分10
16秒前
乔凌云完成签到 ,获得积分10
17秒前
天天快乐的应助被学术雷锋采纳,获得10
18秒前
陨落的繁星完成签到,获得积分10
18秒前
务实青筠完成签到 ,获得积分10
19秒前
nusiew完成签到,获得积分10
19秒前
勤奋的毛豆完成签到,获得积分10
19秒前
爱沉淀的太阳花完成签到,获得积分10
20秒前
热心的梦柏完成签到 ,获得积分10
21秒前
织梦完成签到 ,获得积分10
21秒前
tszjw168发布了新的文献求助10
22秒前
szj完成签到,获得积分10
22秒前
星星完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719706
捐赠科研通 7748769
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428